Skip to Main Content

Author Details

Alison R Moliterno
Johns Hopkins Hospital
1995
97
30
Prashant Mali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36181657Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency.Int J Hematol2023
37216688Silent cerebral infarction during immune TTP remission: prevalence, predictors, and impact on cognition.Blood2023
36543879Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms.Leukemia2023
36745865JAK2 V617F allele burden in polycythemia vera: burden of proof.Blood2023
36647302Characterization of myeloproliferative neoplasms in the paediatric and young adult population.Br J Haematol2023
34461629Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission.Blood Adv2022
35932324Maternal and fetal outcomes of pregnancy occurring after a diagnosis of immune-mediated thrombotic thrombocytopenic purpura.Ann Hematol2022
35286385HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression.Blood2022
35153002The roles of sex and genetics in the MPN.Int Rev Cell Mol Biol2022
35179961The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia.Sci Adv2022
33179792Reduced sensitivity of PLASMIC and French scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals.Transfusion2021
33683339Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome.Blood Adv2021
33807519Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology.Int J Mol Sci2021
33777803The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN.Front Oncol2021
34460124Major adverse cardiovascular events in survivors of immune-mediated thrombotic thrombocytopenic purpura.Am J Hematol2021
34563606Interaction of the inflammatory response and megakaryocytes in COVID-19 infection.Exp Hematol2021
33990660Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features.NPJ Precis Oncol2021
34247039Clinical applications of thrombopoietin silencing: A possible therapeutic role in COVID-19?Cytokine2021
34183535Thrombosis in myeloproliferative neoplasms: update in pathophysiology.Curr Opin Hematol2021
34269797Continuous-infusion von Willebrand factor concentrate is effective for the management of acquired von Willebrand disease.Blood Adv2021
34209587Germline <i>ERBB2</i>/<i>HER2</i> Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms.Cancers (Basel)2021
34028801Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.Br J Haematol2021
33237986Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.Blood2021
32479500Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.PLoS One2020
31840276Solvent detergent treated pooled plasma and reduction of allergic transfusion reactions.Transfusion2020
31940353Gamma gap thresholds and HIV, hepatitis C, and monoclonal gammopathy.PLoS One2020
32624445Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.Clin Lymphoma Myeloma Leuk2020
32542392Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden.Blood Adv2020
32322810Inflammation exerts a nonrandom risk in the acquisition and progression of the MPN: Insights from a Mendelian randomization study.EClinicalMedicine2020
30692098<i>BRCA1</i> Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated <i>miR-155</i> to Disrupt Myeloid Differentiation in Myeloid Malignancies.Clin Cancer Res2019
31294330Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention.Res Pract Thromb Haemost2019
30944118Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis.Cancer Discov2019
29335737Shedding New Light on the Magnitude of Thrombosis Risk in Patients With Myeloproliferative Neoplasms.Ann Intern Med2018
30075527A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis.Medicine (Baltimore)2018
30057941Educational Case: Iron Overload and Hemochromatosis.Acad Pathol2018
29627078The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: Opportunities for targeted therapy.Blood Rev2018
28543980Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension.Am J Hematol2017
28461395Eculizumab cessation in atypical hemolytic uremic syndrome.Blood2017
28395806Generation of human iPSCs from an essential thrombocythemia patient carrying a V501L mutation in the MPL gene.Stem Cell Res2017
28948454Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.Curr Hematol Malig Rep2017
29042365Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.Blood2017
28932692Patient with antiphospholipid syndrome presenting with testicular torsion-like symptoms.Urol Case Rep2017
27068855Carotidynia Heralding the Onset of Acute Leukemia.Am J Med2016
26493756Pernicious Emboli: An Uncommon Cause of a Common Problem.Am J Med2016
27697978Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post-JAK2 V617F Discovery Era.J Natl Compr Canc Netw2016
27313483Development of paroxysmal nocturnal hemoglobinuria in CALR-positive myeloproliferative neoplasm.J Blood Med2016
25993152From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management.Am Soc Clin Oncol Educ Book2015
26629820The Gamma Gap and All-Cause Mortality.PLoS One2015
26324368Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.J Clin Oncol2015
26043391Thrombotic microangiopathy: focus on atypical hemolytic uremic syndrome.Hematol Oncol Clin North Am2015
  • 1 - 50 of 97

Recommended Authors

Zhijie Wu
and Blood Institute, National Institutes of Health
Career Start Year 2013
Number of shared co-authors 1
Srinivas K Tantravahi
Huntsman Cancer Institute at the University of Utah.
Career Start Year 2012
Number of shared co-authors 3
Alexa J Siddon
Yale School of Medicine
Career Start Year 2010
Number of shared co-authors 1
Dongqing Yan
Inner Mongolia University
Career Start Year 2010
Number of shared co-authors 1
Kim-Hien T Dao
Astex Pharmaceuticals
Career Start Year 2009
Number of shared co-authors 5
Jennifer Dunlap
Oregon Health & Science University
Career Start Year 2008
Number of shared co-authors 2
Siob??n B Keel
University of Washington School of Medicine
Career Start Year 2007
Number of shared co-authors 2
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 0
Naseema Gangat
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 4
Guang Fan
Oregon Health and Science University
Career Start Year 2000
Number of shared co-authors 3
Xingmin Feng
and Blood Institute, National Institutes of Health
Career Start Year 1999
Number of shared co-authors 2
Sze Fai Yip
Tuen Mun Hospital
Career Start Year 1999
Number of shared co-authors 0
Angela G Fleischman
University of California Irvine
Career Start Year 1998
Number of shared co-authors 3
Vilmarie Rodriguez
Nationwide Children's Hospital
Career Start Year 1998
Number of shared co-authors 0
Markus G Seidel
Medical University of Graz
Career Start Year 1998
Number of shared co-authors 0
Luca Malcovati
University of Pavia & S. Matteo Hospital
Career Start Year 1997
Number of shared co-authors 6
Stephanie Halene
Smilow Cancer Center, Yale University School of Medicine
Career Start Year 1997
Number of shared co-authors 1
David P Steensma
Novartis Institutes for BioMedical Research
Career Start Year 1997
Number of shared co-authors 5
Rachel J Cook
Oregon Health and Science University
Career Start Year 1997
Number of shared co-authors 0
Alfred I Lee
Yale University School of Medicine
Career Start Year 1996
Number of shared co-authors 0
Suzanne M Vercauteren
Clinical Immunology Lab, BC Children's Hospital
Career Start Year 1996
Number of shared co-authors 0
Robert Kralovics
Medical University of Vienna
Career Start Year 1995
Number of shared co-authors 1
Thomas J Raife
University of Wisconsin School of Medicine and Public Health
Career Start Year 1994
Number of shared co-authors 1
Christoph Klein
Kinderklinik und Kinderpoliklinik der Ludwig-Maximilians-Universitat Munchen
Career Start Year 1993
Number of shared co-authors 0
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 1
Richard D Press
Oregon Health and Science University
Career Start Year 1988
Number of shared co-authors 3
Kim E Nichols
St. Jude Children's Research Hospital
Career Start Year 1986
Number of shared co-authors 1
Kenneth B Miller
Tufts Medical Center
Career Start Year 1981
Number of shared co-authors 1
Ulrich D??hrsen
University Hospital Essen, University of Duisburg-Essen
Career Start Year 1979
Number of shared co-authors 2
Neal S Young
National Heart Lung and Blood Institute Division of Intramural Research
Career Start Year 1972
Number of shared co-authors 5

Collaborators

Jerry L Spivak
The Johns Hopkins University School of Medicine
Co-authored papers 27
Donna M Williams
Johns Hopkins University School of Medicine
Co-authored papers 16
Robert A Brodsky
Sidney Kimmel Cancer Center, Johns Hopkins University
Co-authored papers 9
Linda M S Resar
Johns Hopkins University School of Medicine
Co-authored papers 6
Richard J Jones
Sidney Kimmel Cancer Center, Johns Hopkins University
Co-authored papers 3
Mark J Levis
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Co-authored papers 3
Zhaohui Ye
Center for Biologics Evaluation and Research
Co-authored papers 3
Huichun Zhan
Stony Brook School of Medicine
Co-authored papers 3
Bartlomiej Przychodzen
Vanda Pharmaceuticals Inc.
Co-authored papers 3
Roxann G Ingersoll
Mc-Kusick-Nathans Institute of Genetic Medicine, Johns Hopkins
Co-authored papers 2
Lisa R Yanek
Co-authored papers 2
Brian T Garibaldi
Johns Hopkins University School of Medicine
Co-authored papers 2
Stephen T Oh
Washington University School of Medicine
Co-authored papers 2
Chi V Dang
Johns Hopkins University School of Medicine
Co-authored papers 2
Jason Gotlib
Stanford University School of Medicine
Co-authored papers 2
Linzhao Cheng
Johns Hopkins University School of Medicine
Co-authored papers 2
Paul M Ness
Johns Hopkins University
Co-authored papers 2
Christopher D Gocke
Johns Hopkins University School of Medicine
Co-authored papers 2
Moshe Talpaz
University of Michigan Rogel Cancer Center.
Co-authored papers 1
Michael J Considine
Johns Hopkins University School of Medicine
Co-authored papers 1
Daniel A Pollyea
University of Colorado Division of Hematology
Co-authored papers 1
Prashant Mali (CM4AI)
University of California San Diego
Co-authored papers 1
Aparna Pallavajjala
Johns Hopkins University School of Medicine
Co-authored papers 1
Richard Koche
Memorial Sloan Kettering Cancer Center
Co-authored papers 1
Victor R Gordeuk
Co-authored papers 1
Yoon-Young Jang
Daegu Catholic University Medical Center, Catholic University of Daegu
Co-authored papers 1
Masako Suzuki
Co-authored papers 1
Yelena Z Ginzburg
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Co-authored papers 1
Seishi Ogawa
Kyoto University
Co-authored papers 1
Satoru Miyano
Tokyo Medical and Dental University
Co-authored papers 1
Release 1.2